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Human  recombinant  single  chain  urokinase-type 
plasminogen activator  (recombinant  scu-PA) and a hy- 
brid  between  human  tissue-type lasminogen activator 
(t-PA)  and  scu-PA,  obtained by ligation of cDNA frag- 
ments  encoding the  NHz-terminal  region  (amino  acids 
1-67) of t-PA  and  the COOH-terminal  region  (amino 
acids 136-41 1) of scu-PA,  were  expressed  in a mam- 
malian cell system. The proteins were purified from 
conditioned culture media containing 2% fetal calf 
serum by chromatography on zinc  chelate-Sepharose, 
immunoadsorption chromatography on an insolubil- 
ized murine monoclonal antibody  directed  against  uro- 
kinase,  benzamidine-Sepharose  chromatography,  and 
Ultrogel AcA 44 gel  filtration.  Between 180 and 230 
pg of the  purified  proteins  were  obtained per liter of 
conditioned medium, with a yield of approximately 
18% and  a  purification  factor of 720-1900. 
On sodium  dodecyl sulfate gel  electrophoresis  under 
reducing conditions, the proteins migrated as single 
bands with approximate M, 50,000 for recombinant 
scu-PA and M, 43,000 for the t-PA/scu-PA hybrid. 
Following  conversion  to  urokinase  with  plasmin, the 
proteins had a specific  amidolytic  activity  comparable 
to that of natural  scu-PA. Both proteins  activated plas- 
minogen directly  with K ,  = 0.53 and 1.4 p~ and k2 = 
0.0034 and 0.0027 s”, respectively.  Both  proteins  did 
not bind specifically to  fibrin  and  had a comparable 
degree of fibrin selectivity as measured in a system 
composed of a whole  human  ‘251-fibrin-labeled  plasma 
clot  suspended  in  human  plasma. 
It is  concluded that  this  chimeric  protein,  consisting 
of the  NH2-terminal  “finger-like” domain of t-PA and 
the COOH-terminal  region of SCU-PA, has  very  similar 
enzymatic  properties as compared  to SCU-PA, but  has 
not acquired  the  fibrin  affinity of t-PA. 
Two physiological plasminogen activators  with  demon- 
strated fibrin  specificity,  namely tissue-type plasminogen ac- 
tivator  (t-PA)’  and single chain  urokinase-type plasminogen 
* The costs of publication of this  article were defrayed in  part by 
the  payment of page  charges. This  article  must  therefore be hereby 
marked  “aduertisement”  in  accordance  with 18 U.S.C. Section 1734 
solely to  indicate  this  fact. 
’ The  abbreviations used are:  t-PA,  tissue-type plasminogen acti- 
vator; u-PA, urokinase-type plasminogen activator; scu-PA, single 
chain  u-PA;  nscu-PA,  natural  scu-PA  obtained from a lung  adeno- 
carcinoma cell line (CALU-3);  rscu-PA,  recombinant  scu-PA  obtained 
by expression of the  cDNA  encoding  scu-PA  (with CysI3l + TrpI3’ 
and Gly”66 + Cys3= mutations) in a mammalian cell system; SDS, 
sodium dodecyl sulfate;  ELISA,  enzyme-linked  immunosorbent assay; 
DMEM, Dulbecco’s modified Eagle’s medium. 
. 
activator  (scu-PA) (I), are  presently  under clinical  investiga- 
tion  as clot-specific thrombolytic  agents (2-9). The molecular 
mechanisms regulating the fibrin  specificity of t-PA  and scu- 
PA  are, however, different.  t-PA is a poor activator of plas- 
minogen in the absence of fibrin, characterized by a high 
Michaelis constant (65 FM). t-PA, however, binds specifically 
to fibrin (Kd = 0.14 p ~ ) ,  and fibrin-associated t-PA has a 
high affinity for plasminogen ( K ,  = 0.16 p M ) .  The fibrin 
specificity of t-PA  thus  appears  to be mediated via its specific 
binding  to  fibrin (10). t-PA  contains  an  NH,-terminal region, 
homologous to  the “finger” domains of fibronectin, which has 
been claimed to be involved in its  binding  to fibrin  (11, 12). 
We have reported  that  scu-PA  has  an  intrinsic plasminogen- 
activating  potential  and  that  the fibrin  specificity of scu-PA 
depends on its single chain structure (13, 14). Others (15), 
however, have reported  that  scu-PA is inactive toward  plas- 
minogen. Our  results  indicate  that  the  activation of plasmin- 
ogen by scu-PA obeys Michaelis-Menten  kinetics  character- 
ized by a low K ,  and  a low k ,  (14). In  plasma, however, scu- 
PA does not  activate plasminogen,  due to  the presence of a 
reversible inhibitor, which is neutralized by fibrin (13). 
On the  basis of these  mechanisms, we hypothesized that  a 
hybrid molecule, consisting of the  NH,-terminal region of t -  
PA (the finger domain) and the COOH-terminal region of 
scu-PA  (the  B-chain  and  a  carboxyl-terminal  remnant of the 
A-chain), might  combine the  fibrin specificity of both mole- 




Natural  scu-PA  (nscu-PA) was  purified  from the  conditioned  me- 
dium of a human lung adenocarcinoma cell line (CALU-3) as de- 
scribed (16). t-PA was  purified  from conditioned melanoma cell 
(Bowes) culture media as described (17). Thrombin (Topostasin“) 
was from Roche (Brussels, Belgium); bovine fibrinogen was from 
Organon (Oss, The Netherlands); aprotinin (TrasyloP) was from 
Bayer AG (Leverkusen-Bayerwerke,  Federal Republic of Germany), 
and pyro-Glu-Gly-Arg-p-nitroanilide (S-2444)  and  D-Val-Leu-Lys-p- 
nitroanilide  (S-2251) were from KabiVitrum  (Brussels, Belgium). 
Human plasminogen and fibrinogen were purified as described (17). 
Plasmin was prepared by streptokinase  activation of human  plasmin- 
ogen (18). The  thrombin  inhibitor D-Ile-Pro-Arg  chloromethyl ketone 
was custom-synthetized a t  Union  Chimique Belge (Brussels, Belgium) 
(19). The  International Reference Preparation of Urokinase  (66/46) 
was obtained from  Dr. P. J. Gaffney (National  Institute for Biological 
Standards  and  Control,  London,  Great  Britain). Zinc chelate-Seph- 
arose was prepared by the  method of Porath  et al. (20).  Sepbadex G- 
100 superfine was from Pharmacia  P-L Biochemicals, and Ultrogel 
AcA 44 was from LKB (Bromma, Sweden). p-Aminobenzamidine 
(Aldrich) was  coupled to  CH-Sepharose 4B (Pharmacia  P-L Biochem- 
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icals)  as described by Holmberg  et al. (21). All other chemicals and 
reagents were of standard  laboratory grade. 
The monoclonal sntibody  MA-4DlE8, which reacts  with  an  epitope 
in  the  B-chain of urokinase, was obtained  as described  elsewhere (22). 
It was coupled to CNBr-activated Sepharose 4B (Pharmacia P-L 
Biochemicals) following the  instructions of the  manufacturer,  with a 
substitution level of 6 mg of antibody/g of gel. Polyclonal rabbit 
antisera  against  u-PA  and  against  t-PA were obtained  as described 
elsewhere  (17, 22). 
Methods 
Construction of Expression Vectors for rscu-PA and for t-PA/scu-PA 
Hybrid 
The urokinase  cDNA clone pULBlOOO (23),  obtained from a cDNA 
library of Detroit 562 carcinoma cells (ATCC  CRL 138), was used. 
This clone encodes a protein which differs in  three  positions  from 
the published urokinase sequence  (24,  25): Cys13' is replaced by 
tryptophan, Gly3@ by cysteine,  and Ala4'' by valine. To reconstruct 
the cDNA  coding for pre-scu-PA,  the  cDNA of  pULBlOOO was  fused 
with a synthetic  adaptor  corresponding  to  the  urokinase signal  pep- 
tide  (25)  up  to  amino acid -16 (26).  In  addition,  the codon  specifying 
Val4'" was replaced by a codon specifying alanine by means of a 
synthetic  linker  (26)  to yield construct ppUK.410 (26). 
The t-PA/scu-PA hybrid cDNA was constructed by fusion of a 
392-bp HindIII-RsaI cDNA fragment, derived from the  t-PA clone 
DSPl.lTPA25.BGH  (26) which encodes  the  NHZ-terminal region (up 
to  amino acid 67) of t-PA via  a synthetic  43-bp  adaptor molecule, to 
a BalI-Sac1  fragment of cDNA,  encoding  amino acids 149-411 of u- 
PA (26).  In  this way, the  NHZ-terminal region of t-PA,  encompassing 
amino acids 1-67, is fused via a tyrosine codon to L Y S ' ~ ~  in u-PA, 
whereby the plasmin cleavage site L y ~ ' ~ ~ - L y s ' ~ ~  in urokinase is de- 
stroyed, yielding construct  Fg.t-PA/UK.410  (26). 
Both  the  recombinant  pre-scu-PA  and  the  pre-t-PA/scu-PA hybrid 
were further subcloned as  HindIII-Sac1  cassettes  into a eukaryotic 
transient expression  vector DSP1.1BGH  (27).  This expression  system 
is  under SV40  early promoter  and bovine  growth hormone polyade- 
nylation  control regions,  which are  flanked by polylinkers with  unique 
SalI sites. Thus, the generated "SalI expression cassettes" can be 
easily obtained from the  transient expression  vector and  inserted  into 
the  unique  SalI  site of a stable plasmid  expression  vector (28).  This 
latter vector contains bovine  polyoma virus sequences and  either  the 
neomycin resistance gene (t-PA/scu-PA hybrid containing  plasmid) 
or  the mouse dihydrofolate  reductase  cDNA  (29)  (scu-PA  containing 
plasmid), which  confer resistance  to G418 and  methotrexate, respec- 
tively.' 
Transfection and Stable  Expression in  Mammalian Cell Systems 
Hamster kidney  cells (27) were maintained  in Dulbecco's modified 
Eagle's medium (DMEM) supplemented with 5% fetal calf serum 
(Gibco/Bethesda  Research  Laboratories,  Gent, Belgium or Flow, 
Irvine, Scotland)  and 2 mM L-glutamine. Transfection was performed 
in 80-cm' tissue culture flasks with approximately 3 X lo6 cells in 
DMEM  supplemented  with 10% fetal calf serum, 2 mM L-glutamine, 
and 50 pg/ml gentamycin  (Sigma) for expression of the  t-PA/scu-PA 
hybrid or in a mixture  (1:l volume) of DMEM/F12 special (Gibco/ 
Bethesda Research Laboratories) lacking thymidine and hypoxan- 
thine  (for expression of scu-PA).  Twenty pg of recombinant  plasmid 
DNA, twice purified by CsCl gradient  centrifugation, was added  to 
the cells  which were transfected  using  the calcium phosphate  copre- 
cipitation procedure (30). After 4 h of incubation, the cells were 
treated with 10% glycerol in DMEM for 3-4 min. After 2 days of 
incubation  in  DMEM,  the cells were subcultured  with a split  ratio of 
1:10 and subjected to selective pressure by addition of either 400 pg/ 
ml G418 (Geneticin, Gibco/Bethesda Research  Laboratories)  in 
DMEM  containing  2%  fetal calf serum  (t-PA/scu-PA hybrid selec- 
tion) or 200-400 nM methotrexate in DMEM/F12 special supple- 
mented with 2% dialyzed fetal calf serum (scu-PA selection). The 
selective  medium was changed after 4-5 days, and 1-3-mm  colonies 
became visible after 11-14 days. These colonies were isolated with a 
cloning  cylinder and  further  propagated,  and  the  culture  supernatants 
were screened  for u-PA-related  antigen by ELISA  and for  amidolytic 
activity  with th'e chromogenic urokinase  substrate S-2444. Cell clones, 
selected on  the  basis of their expression level of both  urokinase-like 
activity  and  u-PA-related  antigen, were further  expanded  to 175-cm2 
- ~ _ _ _ _ _ ~ _ _ _ _ _ _ _ ~ .  
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cell culture  flasks  (Gibco/Bethesda  Research  Laboratories)  and  main- 
tained  and passaged under  standard  culturing  conditions with split 
ratios of 1: lO to 1:15 a t  weekly intervals.  Finally, two clones  (clone 
31 for rscu-PA  and clone 138 for the  t-PA/scu-PA  hybrid) secreting, 
respectively, between 2 and 5 pg/ml or between 0.6 and 2 pg/ml 
urokinase equivalent (S-2444 amidolytic) activity per 48 h when 
cultured  in 175-cmZ flasks  containing 50 ml of medium were selected 
for larger scale production of conditioned medium. Seven 175-cm' 
flasks of each clone were used to inoculate a 6000-cm' Nunc cell 
factory  (Gibco/Bethesda  Research  Laboratories)  containing  1.8  liters 
of DMEM  supplemented with 2%  fetal calf serum  and 50 pg/ml  of 
gentamycin. At 2- or 3-day intervals, the conditioned medium was 
harvested,  and  aprotinin  (Sigma) was  added to a final  concentration 
of 20 pg/ml. After  three  harvests,  the c ll monolayers began to  detach; 
and  therefore,  the cell factories were discarded. 
Assay Techniques 
ELISA utilizing rabbit  anti-urokinase IgG-coated  polystyrene 
plates and the murine monoclonal antibody MA-4DlE8, directed 
against an epitope in the B-chain of urokinase, was performed as 
described elsewhere (22). Clot lysis was assayed as described (22). 
Binding of u-PA  to  fibrin was performed  in  thrombin-clotted  citrated 
human  plasma  or buffer containing plasminogen-free human  fibrin- 
ogen (13).  SDS-polyacrylamide gel electrophoresis was performed on 
12% slab gels according to Laemmli (31), and immunoblotting on 
nitrocellulose sheets was  performed  according to  Towbin  et al. (32). 
Amino  acid analysis was  performed on a Beckman 119CL amino acid 
analyzer after 20 h of hydrolysis in 6 M HC1 a t  110 "C in uacuo. 
Specific activities were determined  on fibrin plates  (33) by compari- 
son with  the  International Reference Preparation of Urokinase. 
Characterization of Purified rscu-PA and  t-PA/scu-PA Hybrid 
Treatment with Plasmin-nscu-PA, rscu-PA, or the  t-PA/scu-PA 
hybrid at  a final  concentration of 1 p~ in 0.038 M NaCI, 0.05 M Tris. 
HC1 buffer, pH 7.4, containing 0.01% Tween 80 was incubated a t  
37 "C  with  plasmin  (final  concentration, 6.8 nM). At timed  intervals 
(10-40 rnin), 10 p1 was removed and added to  800 pl of the same 
buffer containing S-2444 at  a  final concentration of  0.3 mM. Uroki- 
nase  activity was determined from measurements of the  absorbance 
a t  405 nm  and expressed in  international  units by comparison  with 
the  International Reference Preparation (66/46). 
Actiuation of Plasminogen in Presence of Excess Plasmin Sub- 
strate-rscu-PA a t  a concentration of 7.5 nM or the t-PA/scu-PA 
hybrid at  a concentration of 10.5 nM was incubated with varying 
concentrations of plasminogen (final concentration, 0.08-1 p M )  in 
0.038 M NaCI, 0.05 M Tris.HC1 buffer, pH 7.4, containing 0.01% 
Tween 80 and 1 mM S-2251 (14). The generation of plasmin was 
determined from the  absorbance  at 405 nm,  monitored over 3 min, 
and expressed in  nanomolar by comparison  with a plasmin  calibration 
Binding to Purified Fibrin-Human fibrinogen (final concentra- 
tion, 0-3.3 mg/ml)  in 0.038 M NaC1, 0.05 M Tris.  HCl buffer, pH 7.4, 
containing 0.01% Tween 80 and 1 mg/ml  bovine serum  albumin was 
mixed with  rscu-PA,  nscu-PA,  the  t-PA/scu-PA hybrid, or  t-PA  (final 
concentration, 50-100 ng/ml). The mixture was clotted by addition 
of thrombin  to a final  concentration of 20 NIH  units/ml. Following 
a 1-min  incubation at  37 "C, thrombin was inactivated by the  addition 
of D-Ile-Pro-Arg chloromethyl  ketone  (final  concentration, 10 p ~ )  to 
prevent  inactivation of urokinase  (34),  and  the  samples were centri- 
fuged for 1 min a t  10,000 X g. The concentrations of u-PA-related 
antigen  in  the  supernatants were determined by ELISA  as described 
above; t-PA was  assayed with  ELISA described  elsewhere (35). 
'*"Z-Fibrin-labeled Plasma Clot Lysis in  Plasma Milieu-The rela- 
tive fibrin  specificity of nscu-PA,  rscu-PA,  the  t-PA/scu-PA hybrid, 
and  t-PA was measured in a system composed of a  '251-fibrin-labeled 
human  plasma  clot  suspended  in  human  citrated  plasma  as de cribed 
elsewhere (18). Fibrinogen levels were measured with a  coagulation 
rate  assay  (36). 
C U N B .  
RESULTS 
Purification and Physicochemical  Characterization of 
rscu-PA and t-PA/scu-PA  Hybrid 
The  results of the  purification of rscu-PA and  the  t-PA/ 
scu-PA hybrid from conditioned culture media are summa- 
rized in Table I. The first purification step involved the 
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TABLE I 1 2 3 4  4 3 2 1  
Purification of rscu-PA and the t-PAlscu-PA hybrid 
(total volume of starting  material 3.8 and 12 liters). The  first  three 
columns are expressed per 1000 ml of starting material. 
""
""
The  data represent mean values of two  independent preparations 4 
Volume  Protein  anti- Yield 
U-PA 
cation 
ml mg mg % -fold 
Starting material 1000 1450 1.40 100 1 
Zinc chelate-sepha- 37 51 0.60  42  12 
Immunoadsorption 4.3  1.2 0.70  49 600 





Ultrogel AcA 44 4.0  0.33 0.23 17 720 
t-PA/scu-PA 
Starting material 1000 1450 0.97 100 1 
Zinc chelate-Sepha- 42 52 0.60 62 16 
Immunoadsorption 4.4 0.75 0.34 35 650 
Benzamidine-Sepha- 6.5 0.45 0.18 18 560 
Ultrogel AcA 44 3.8 0.13 0.18 18 1900 
rose 
rose 
l a   l b  2a  b 3 4 l a   l b  2a  2b 3 4 
A B 
FIG. 2. Immunoblotting of nonreduced SDS gels. A ,  with 
anti-u-PA antiserum; B, with anti-t-PA antiserum.  Lane 1, t-PA, lane 
2, nscu-PA; lane 3, rscu-PA;  lane 4 ,  t-PAIscu-PA hybrid. 
TABLE I1 
Amino acid composition of scu-PA and the  t-PAlscu-PA hybrid 
The numbers of amino acids were normalized to a total of 378 for 
the t-PA/scu-PA hybrid, which is the number of amino  acids (exclud- 
ing  cysteine and  tryptophan, which were not determined) expected 
from the primary sequences (23-26,39). The  data represent the means 
of three analyses. 
m 0 nscu-PA, 377 for rscu-PA (Gly366 + Cys3% substitution),  and 315 for 
A D 
FIG. 1. Sodium dodecyl sulfate-polyacrylamide gel electro- 
phoresis. A, without reduction; B, after reduction with dithioeryth- 
ritol. Lune I, rscu-PA (preparations u and b); lane 2, t-PAIscu-PA 
hybrid (preparations a and b); lane 3, nscu-PA from CALU-3; lane 4, 
calibration  mixture containing phosphorylase  b (M, 94,000), albumin 
(M, 67,000), ovalbumin (M, 43,000), carbonic anhydrase (M, 30,000), 
soybean trypsin inhibitor (M, 20,000), and  a-lactalbumin (M, 14,400). 
application of between 3.8 or  12  liters of conditioned media 
to a 5 X 10-cm column of zinc chelate-Sepharose, previously 
equilibrated  with 0.3 M NaC1,  0.2 M Tris. HC1 buffer, pH 7.5, 
containing 0.01% Tween 80 and 10 kallikrein inhibitor  units/ 
ml aprotinin  (Bayer),  at a flow rate of 100  ml/h at  4 "C. Only 
between 50 and 70% of the  u-PA-related  antigen was adsorbed 
during  the  first passage, and  the  material was therefore recy- 
cled on  a second column. After the conditioned  media were 
applied, the column was washed with  equilibration  buffer and 
eluted  with  buffer containing 50 mM imidazole, collecting 20- 
Amino 
acid nscu-PA rscu-PA Sequence 
t-PA/scu-PA 
hvbrid Sequence 
Asx 39 38 
Thr 23  26 
Ser 32  32 
Glx 43  43 
Pro 31 29 
Ala 18 15 
Val 16 14 
Met 6  7 
Ile 16 12 
Leu 28 30 
TYr 15 17 
Phe 13  12 
His 13  16 
LYS 24  27 
Arg 23  22 
G ~ Y  38 34 
37  24  22 
26  23 22 
30  29  29 
40  43 40 
23  20 19 
35 (34) 28 25 
16 13  13 
19 17 17 
7  6 6 
19  13  19 
31 26  25 
18 15 16 
12 11 10 
17 11 11 
26  20  20 
22  19 21 
ml fractions.  Fibrinolytic  activity, as measured by clot lysis, 
and u-PA-related antigen, as measured by ELISA, eluted 
together  in a peak  partially separated from the major protein 
peak.  A recovery of u-PA-related  antigen of 40-60% with 12- 
16-fold purification and 20-30-fold reduction in volume was 
achieved. Aliquots of about 100 ml of these pooled fractions 
were then chromatographed  on  a 0.8 X 5-cm immunoadsorp- 
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FIG. 3.  Generation of  amidolytic activity by treatment  with 
plasmin. 0, nscu-PA; e, rscu-PA; W, t-PA/scu-PA hybrid. 
FIG. 4. Lineweaver-Burk plot of activation of plasminogen. 
0, rscu-PA (7 .5 nM); W, t-PA/scu-PA hybrid (10.5 nM). 
.21 .42  .a3 1.67 3.34 
FIBRIN mgl rn l  
FIG. 5. Binding to fibrin clots. A, nscu-PA; W, rscu-PA; V, t- 
PA/scu-PA hybrid 0, t-PA. Concentrations of u-PA- or t-PA-related 
antigen were measured in the supernatant after thrombin-induced 
clotting of purified human fibrinogen. 
tion column at  a flow rate of 3  ml/h.  The column was washed 
with 0.3 M NaCl, 0.02 M Tris.HC1 buffer, pH 7.5, containing 
0.01% Tween 80 and 10 kallikrein inhibitor units/ml apro- 
tinin  and  then  eluted with 2 M KSCN in the  same buffer. The 
fractions containing u-PA-related antigen were pooled, di- 
alyzed against buffer, and passed over a 0.6 X 3-cm column 
of benzamidine-Sepharose at  a flow rate of 2 ml/h. This 
procedure efficiently eliminated small amounts of contami- 
nating  urokinase  (reduction from  between  1.5 and 2% to less 
than  0.3%).  The  eluates were concentrated  to 10 ml by dialysis 
against solid polyethylene glycol 20,000 (Merck), and final 
purification was obtained by gel filtration  on  a 1.6 x 90-cm 
column of Ultrogel AcA  44 equilibrated with 0.3 M NaC1,0.02 
M Tris.HC1  buffer,  pH 7.5, containing 0.01% Tween 80 and 
10  kallikrein inhibitor  units/ml  aprotinin.  Table I summarizes 
the yields and purification factors in the consecutive purifi- 
cation  steps  obtained with two independent  preparations of 
rscu-PA  and  the  t-PA/scu-PA hybrid. The specific activities 
of the final products measured on fibrin plates were 63,000 
IU/mg  for  rscu-PA  and 33,000 IU/mg for the  t-PA/scu-PA 
hybrid. 
The purified proteins were analyzed by SDS-polyacryl- 
amide gel electrophoresis as shown in Fig. 1. Purified rscu- 
PA migrated as  a  triplet  band  under  nonreducing  conditions 
but  as  a single main  band with M ,  -50,000 under reducing 
conditions. All three  bands seen on  the unreduced gels rep- 
resented  rscu-PA  as evidenced by their reactivity  with uroki- 
nase  antiserum  on  immunoblotting (Fig. W). The purified t -  
PA/scu-PA hybrid also migrated as a triplet band under 
nonreducing  conditions  and  as  one broad band with M ,  
-43,000 under reducing conditions (Fig. 1). All bands reacted 
with antibodies against u-PA (Fig. W )  and also, but very 
weakly, with antibodies  against  t-PA  (Fig. 2B).  
The  amino acid  compositions of rscu-PA  and  the  t-PA/scu- 
PA  hybrid are  represented in Table 11. The observed amino 
acid  compositions are in agreement with those derived  from 
the known sequences of rscu-PA  and  the  t-PA/scu-PA hybrid. 
Functional Characterization of rscu-PA and 
t-PA/scu-PA Hybrid 
Generation of Amidolytic Activity following Treatment with 
Plasmin-Plasmin (0.7% on a molar basis) causes a time- 
dependent conversion of nscu-PA, rscu-PA, and the t-PA/ 
scu-PA hybrid to amidolytically active urokinase (Fig. 3). 
Maximal conversion results in an amidolytic activity meas- 
ured with S-2444, corresponding to  a specific activity of about 
70,000 IU/mg for nscu-PA, 67,000 IU/mg for rscu-PA, and 
49,000 IU/mg for the  t-PA/scu-PA hybrid. 
Kinetics of Activation of Plasminogen-The activation of 
plasminogen by both rscu-PA and the t-PA/scu-PA hybrid 
obeys Michaelis-Menten kinetics, as evidenced by linear  dou- 
ble reciprocal plots of the  initial  activation  rate ( 0 )  versus the 
plasminogen concentration ([PI) (Fig. 4). From these Line- 
weaver-Burk  plots, K, = 0.53 FM and k ,  = 0.0034 s" for rscu- 
PA  and K ,  = 1.4 PM and k2 = 0.0027 s" for the  t-PA/scu-PA 
hybrid were obtained, which are similar to the constants 
previously reported for nscu-PA (16, 37). 
Binding to Fibrin-Fig. 5 illustrates that nscu-PA, rscu- 
PA, and  the  t-PA/scu-PA hybrid,  in contrast  to t-PA, do not 
bind specifically to fibrin. 
Thrombolytic Properties-rscu-PA, the t-PA/scu-PA hy- 
brid,  and  nscu-PA caused a very similar  time-  and  concentra- 
tion-dependent lysis of a "'I-fibrin-labeled clot  immersed  in 
citrated  human  plasma (Fig. 6). Clot lysis was associated  with 
comparable  degrees of fibrinogen degradation, which at  equi- 
potent doses, was more pronounced  than  that observed  with 
t-PA. 
DISCUSSION 
The molecular structures involved in the fibrin  specificity 
of t-PA  and  scu-PA  are different. The clot  selectivity of t-PA 
is mediated via its binding to fibrin (lo),  and the NH,- 
terminal  finger-like  domain  has been claimed to be involved 
in this interaction (11, 12). We have hypothesized that  the 
fibrin  specificity of scu-PA  depends on its single chain  struc- 
ture (13, 14); and recently, it was demonstrated that the 
amino-terminal region is not involved in this  interaction  (22). 
Based on  the  hypothesis  that  the  structures in t-PA  and  scu- 
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TIME IN HOURS 
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TIME M HOURS 
FIG. 6. Lysis  of  lZ5I-fibrin-labeled human plasma clots immersed  in  human  plasma. A ,  rscu-PA at 0.5 
(a), 1 (V), 2 (A), and 4 (0) Fg/ml; B, t-PA/scu-PA hybrid at  0.5 (a), 1 (V), 2 (A), and 4 (0) pg/ml; C, t-PA  at  35 
(H), 70 (V), 150 (A), and 300 (0) ng/ml; D, nscu-PA at 0.5 (a) 1 (V), 2 (A), and 4 (0) pg/ml. 
PA responsible  for fibrin  binding  are localized in  independent, 
autonomously folding domains ( la) ,  we have purified and 
functionally  characterized  a hybrid protein,  obtained by fu- 
sion of the cDNA encoding the finger region of t-PA (67 
amino-terminal  amino  acids)  to  that encoding the carboxyl- 
terminal region of u-PA  (amino  acids 136-411), and  compared 
it with rscu-PA,  obtained by expression of the cDNA  encoding 
full-length  scu-PA in eukaryotic cells. 
rscu-PA was obtained in the single chain form by prevent- 
ing  conversion to  two-chain  u-PA  during  purification by ad- 
dition of aprotinin  to  all buffers. The resulting  protein was 
indistinguishable from nscu-PA  on  the  basis of its M ,  (reduced 
SDS gels), amino acid composition, specific activity, and 
reactivity with  anti-u-PA  antiserum. However, on  nonreduced 
SDS gels, its mobility was significantly faster than that of 
scu-PA.  This may be due to  abnormal folding of the  rscu-PA 
protein, which differs in two amino acids from the natural 
scu-PA. Indeed, the rscu-PA expressed by the pULBlOOO 
cDNA  has Cys':'' + Trp'"' and Gly"fifi + substitutions, 
which may give rise to  the  formation of a Cy~~ ' -Cys '~~ '  disulfide 
bond, which is not  present  in  the  natural  protein.  In  this case,
the  incorrect folding of the  protein does,  however, no longer 
appear  to  alter  its  enzymatic  properties. 
The t-PA/scu-PA hybrid migrated on both reduced and 
unreduced  SDS gels in a position compatible  with  its  antici- 
pated M ,  of 43,000, although  the  band  on reduced gels was 
unexpectedly  broad and  stained only weakly. Thus,  the  t-PA/ 
scu-PA hybrid was also obtained with an  intact L y ~ ~ ~ ~ - I l e ~ ' ~  
peptide bond. The hybrid protein,  with  a very low intrinsic 
amidolytic activity, was converted  to  an amidolytically active 
two-chain structure by plasmin. It activated plasminogen 
obeying Michaelis-Menten kinetics, with kinetic constants 
very similar to those of rscu-PA. It did, however, not bind 
specifically to  fibrin.  In  a  plasma milieu, the hybrid protein 
had  a relative  fibrin  specificity comparable,  but  not  superior, 
to  that of rscu-PA. Thus, surprisingly, fusion of the finger 
domain of t-PA  to  the  truncated  scu-PA did not confer  affinity 
for fibrin to  the hybrid molecule. This may be due to  the  fact 
that,  contrary  to our  working hypothesis,  the finger region of 
t-PA is not  the  main  domain responsible for  the fibrin binding 
of t-PA,  as indeed has been  recently demonstrated (12, 38). 
Alternatively, by fusion of the  amino-terminal 67 amino acids 
in t-PA  to  the  truncated  scu-PA, C y P  of t-PA, located  in the 
epidermal growth factor-like domain, can no longer form a 
disulfide bond with Cys':', but  instead, might react with the 
mutagenized Cys""  of rscu-PA. This would, however, not 
explain  an incorrect,  folding ofthe finger  region, if this region 
indeed constitutes  an  autonomous  structural  and  functional 
domain (12). 
In conclusion, the  present  study shows that  the  truncated 
rscu-PA may serve as  an  acceptor for fusion of t-PA  domains 
to its amino-terminal  end,  without loss of its enzymatic prop- 
erties. Whether fusion proteins of other  domains of the  t-PA 
molecule with this truncated rscu-PA, such as constructed 
and described elsewhere (as),  may constitute plasminogen 
activators with  improved  fibrin  selectivity remains  to be in- 
vestigated. 
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